Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06092931 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
A Phase 1 study, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06092931 is a Phase 1 study that has completed, run by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. The registered enrollment target is 28 participants.
The verdict
NCT06092931, a Phase 1 study, has completed, sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.
Interventions
- DRUG Midazolam
- DRUG Rosuvastatin
- DRUG Digoxin
- DRUG Repaglinide
- DRUG DC-806
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-10-16 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06092931
The ClinicalTrials.gov registry entry for NCT06092931 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Midazolam is the first listed.
NCT06092931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06092931 about?
NCT06092931 is a clinical study titled "A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants". The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breas...
What is the current status of trial NCT06092931?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-10-16. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT06092931?
The interventions under investigation include: Midazolam (DRUG), Rosuvastatin (DRUG), Digoxin (DRUG), Repaglinide (DRUG), DC-806 (DRUG).
Who is sponsoring clinical trial NCT06092931?
This trial is sponsored by DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.